Tuberculosis Risk in Ankylosing Spondylitis, Other Spondyloarthritis, and Psoriatic Arthritis in Sweden: A Population-Based Cohort Study

Arthritis Care and Research

Volumn 70, Issue 10, 2018, Pages 1563-1567

  de Vries, Mirjam K ^a   Arkema, Elizabeth V ^b   Jonsson, Jerker ^c   Bruchfeld, Judith ^c   Jacobsson, Lennart T H ^d   Askling, Johan ^a   Klareskog, Lars ^e   van Vollenhoven, Ronald ^e   Feltelius, Nils ^e   Baecklund, Eva ^e   Kastbom, Alf ^e   Rantapää Dahlqvist, Solbritt ^e   Forsblad d'Elia, Helena ^e   Jacobsson, Lennart ^e   Turesson, Carl ^e   Lindqvist, Elisabeth ^e   Ernestam, Sofia ^e  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b SWEDISH INSTITUTE FOR INFECTIOUS DISEASE CONTROL   (Sweden)

^c KAROLINSKA INSTITUTE   (Sweden)

^d UNIVERSITY OF GOTHENBURG   (Sweden)

^e Sahlgrenska Academy at University of Gothenburg ^*

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR INHIBITOR; BIOLOGICAL FACTOR;

ADULT; AGE DISTRIBUTION; ANKYLOSING SPONDYLITIS; ARTICLE; BIRTHPLACE; COHORT ANALYSIS; CONFIDENCE INTERVAL; CONTROLLED STUDY; DISEASE REGISTRY; FEMALE; HAZARD RATIO; HUMAN; INCIDENCE; INFECTION RISK; MAJOR CLINICAL STUDY; MALE; POPULATION RESEARCH; PSORIATIC ARTHRITIS; SEX DIFFERENCE; SPONDYLARTHRITIS; SWEDEN; TUBERCULOSIS; AGED; CHEMICALLY INDUCED; MIDDLE AGED;

ADULT; AGED; ARTHRITIS, PSORIATIC; BIOLOGICAL FACTORS; COHORT STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; SPONDYLITIS, ANKYLOSING; SWEDEN; TUBERCULOSIS;

EID: 85052961241     PISSN: 2151464X     EISSN: 21514658     Source Type: Journal    
DOI: 10.1002/acr.23487     Document Type: Article

References (15)

1. Carmona L, Gomez-Reino JJ, and the BIOBADASER Group. Survival of TNF antagonists in spondylarthritis is better than in rheumatoid arthritis: data from the Spanish registry BIOBADASER. Arthritis Res Ther 2006;8:R72
2. Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti-TNF therapy: experience with 192 patients. Clin Rheumatol 2008;27:1083–6
3. Kim HW, Park JK, Yang JA, Yoon YI, Lee EY, Song YW, et al. Comparison of tuberculosis incidence in ankylosing spondylitis and rheumatoid arthritis during tumor necrosis factor inhibitor treatment in an intermediate burden area. Clin Rheumatol 2014;33:1307–12
4. Baeten D, Kruithof E, van den Bosch F, van den Bossche N, Herssens A, Mielants H, et al. Systematic safety follow up in a cohort of 107 patients with spondyloarthropathy treated with infliximab: a new perspective on the role of host defence in the pathogenesis of the disease? Ann Rheum Dis 2003;62:829–34
5. Titton DC, Silveira IG, Louzada-Junior P, Hayata AL, Carvalho HM, Ranza R, et al. Brazilian biologic registry: BiobadaBrasil implementation process and preliminary results. Rev Bras Reumatol 2011;51:152–60
6. Tubach F, Salmon D, Ravaud P, Allanore Y, Goupille P, Breban M, et al. Risk of tuberculosis is higher with anti-tumor necrosis factor monoclonal antibody therapy than with soluble tumor necrosis factor receptor therapy: the three-year prospective French Research Axed on Tolerance of Biotherapies registry. Arthritis Rheum 2009;60:1884–94
7. Jung SM, Ju JH, Park MS, Kwok SK, Park KS, Kim HY, et al. Risk of tuberculosis in patients treated with anti–tumor necrosis factor therapy: a nationwide study in South Korea, a country with an intermediate tuberculosis burden. Int J Rheum Dis 2015;18:323–30
8. Cantini F, Niccoli L, Goletti D. Adalimumab, etanercept, infliximab, and the risk of tuberculosis: data from clinical trials, national registries, and postmarketing surveillance. J Rheumatol Suppl 2014;91:47–55
9. Wallis RS, Broder MS, Wong JY, Hanson ME, Beenhouwer DO. Granulomatous infectious diseases associated with tumor necrosis factor antagonists. Clin Infect Dis 2004;38:1261–5
10. Lee SK, Kim SY, Kim EY, Jung JY, Park MS, Kim YS, et al. Mycobacterial infections in patients treated with tumor necrosis factor antagonists in South Korea. Lung 2013;191:565–71
11. Lindstrom U, Exarchou S, Sigurdardottir V, Sundstrom B, Askling J, Eriksson JK, et al. Validity of ankylosing spondylitis and undifferentiated spondyloarthritis diagnoses in the Swedish National Patient Register. Scand J Rheumatol 2015;44:369–76
12. Wadstrom H, Eriksson JK, Neovius M, Askling J, and the ARTIS Study Group. How good is the coverage and how accurate are exposure data in the Swedish Biologics Register (ARTIS)? Scand J Rheumatol 2015;44:22–8
13. Arkema EV, Jonsson J, Baecklund E, Bruchfeld J, Feltelius N, Askling J. Are patients with rheumatoid arthritis still at an increased risk of tuberculosis and what is the role of biological treatments? Ann Rheum Dis 2015;74:1212–7
14. Germano V, Cattaruzza MS, Osborn J, Tarantino A, Di Rosa R, Salemi S, et al. Infection risk in rheumatoid arthritis and spondyloarthropathy patients under treatment with DMARDs, corticosteroids and TNFα antagonists. J Transl Med 2014;12:77
15. Askling J, Fored CM, Geborek P, Jacobsson LT, van Vollenhoven R, Feltelius N, et al. Swedish registers to examine drug safety and clinical issues in RA. Ann Rheum Dis 2006;65:707–12